Matinas BioPharma Holdings, Inc. (MTNB)
USD 0.49
(-8.8%)
USD 0.49
(-8.8%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -22.94 Million USD | -76.27% |
| 2022 | -13.01 Million USD | 38.53% |
| 2021 | -21.17 Million USD | -2.79% |
| 2020 | -20.59 Million USD | -32.17% |
| 2019 | -15.58 Million USD | -10.67% |
| 2018 | -14.08 Million USD | 9.06% |
| 2017 | -15.48 Million USD | -103.8% |
| 2016 | -7.59 Million USD | 16.82% |
| 2015 | -9.13 Million USD | 10.62% |
| 2014 | -10.22 Million USD | -175.27% |
| 2013 | -3.71 Million USD | -3098.9% |
| 2012 | -116.07 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -5.82 Million USD | -9.6% |
| 2024 Q2 | -5.71 Million USD | 1.8% |
| 2023 Q1 | -5.44 Million USD | -16605.05% |
| 2023 Q2 | -6.06 Million USD | -11.4% |
| 2023 Q4 | -5.31 Million USD | 12.24% |
| 2023 Q3 | -6.05 Million USD | 0.08% |
| 2023 FY | -22.94 Million USD | -76.27% |
| 2022 Q2 | -5.91 Million USD | -136.78% |
| 2022 Q1 | -2.5 Million USD | 62.68% |
| 2022 FY | -13.01 Million USD | 38.53% |
| 2022 Q4 | -32.56 Thousand USD | 99.4% |
| 2022 Q3 | -5.46 Million USD | 7.76% |
| 2021 Q3 | -6.83 Million USD | -42.69% |
| 2021 Q4 | -6.69 Million USD | 2.01% |
| 2021 FY | -21.17 Million USD | -2.79% |
| 2021 Q2 | -4.79 Million USD | 3.33% |
| 2021 Q1 | -4.95 Million USD | 21.84% |
| 2020 FY | -20.59 Million USD | -32.17% |
| 2020 Q3 | -5.44 Million USD | 2.87% |
| 2020 Q2 | -5.61 Million USD | -11.19% |
| 2020 Q1 | -5.04 Million USD | 9.46% |
| 2020 Q4 | -6.34 Million USD | -16.36% |
| 2019 Q3 | -4.4 Million USD | -31.68% |
| 2019 Q1 | -4.05 Million USD | -11.7% |
| 2019 FY | -15.58 Million USD | -10.67% |
| 2019 Q4 | -5.57 Million USD | -26.53% |
| 2019 Q2 | -3.34 Million USD | 17.43% |
| 2018 Q4 | -3.62 Million USD | -23.53% |
| 2018 FY | -14.08 Million USD | 9.06% |
| 2018 Q3 | -2.93 Million USD | 13.94% |
| 2018 Q1 | -4.11 Million USD | -13.29% |
| 2018 Q2 | -3.41 Million USD | 17.01% |
| 2017 Q4 | -3.62 Million USD | -6.87% |
| 2017 FY | -15.48 Million USD | -103.8% |
| 2017 Q3 | -3.39 Million USD | 14.44% |
| 2017 Q2 | -3.96 Million USD | 11.75% |
| 2017 Q1 | -4.49 Million USD | -137.66% |
| 2016 Q2 | -1.62 Million USD | 27.65% |
| 2016 Q4 | -1.89 Million USD | -2.9% |
| 2016 Q3 | -1.83 Million USD | -13.21% |
| 2016 Q1 | -2.24 Million USD | -11.89% |
| 2016 FY | -7.59 Million USD | 16.82% |
| 2015 FY | -9.13 Million USD | 10.62% |
| 2015 Q4 | -2 Million USD | 6.89% |
| 2015 Q3 | -2.15 Million USD | 10.39% |
| 2015 Q2 | -2.4 Million USD | 6.44% |
| 2015 Q1 | -2.57 Million USD | 15.58% |
| 2014 Q1 | -2.13 Million USD | -18.75% |
| 2014 Q4 | -3.04 Million USD | -16.56% |
| 2014 Q2 | -2.42 Million USD | -13.41% |
| 2014 FY | -10.22 Million USD | -175.27% |
| 2014 Q3 | -2.61 Million USD | -7.67% |
| 2013 Q3 | -1.45 Million USD | -324.2% |
| 2013 Q2 | -343.31 Thousand USD | -206.17% |
| 2013 Q1 | -112.13 Thousand USD | -18.83% |
| 2013 Q4 | -1.8 Million USD | -23.69% |
| 2013 FY | -3.71 Million USD | -3098.9% |
| 2012 FY | -116.07 Thousand USD | 0.0% |
| 2012 Q4 | -94.36 Thousand USD | -935.34% |
| 2012 Q3 | -9114.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 20.786% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -165.778% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 66.772% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 53.005% |
| Azitra, Inc. | -11.28 Million USD | -103.318% |
| Can-Fite BioPharma Ltd. | -7.63 Million USD | -200.524% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -210.834% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 21.475% |
| CEL-SCI Corporation | -32.36 Million USD | 29.117% |
| iBio, Inc. | -24.9 Million USD | 7.889% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | -6.777% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | -16.027% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -51.161% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | -137.988% |
| NanoViricides, Inc. | -8.29 Million USD | -176.605% |
| Oragenics, Inc. | -20.65 Million USD | -11.068% |
| BiomX Inc. | -26.16 Million USD | 12.331% |
| BiomX Inc. | -26.16 Million USD | 12.331% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 376.011% |
| Palatin Technologies, Inc. | -29.73 Million USD | 22.848% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 49.263% |
| Theriva Biologics, Inc. | -18.34 Million USD | -25.031% |